David A. Ricks serves as the Chair, President, and Chief Executive Officer of Eli Lilly and Company, a global pharmaceutical leader headquartered in Indianapolis, Indiana. Ricks joined Eli Lilly in 1996 and has since climbed the ranks, showcasing his dedication and strategic vision. His journey within the company began in various sales and marketing roles, eventually leading him to significant leadership positions. Before assuming his current roles, Ricks was the President of Lilly Bio-Medicines, where he oversaw the development and commercialization of treatments for complex diseases such as cancer and autoimmune disorders. Under Ricks' leadership, Eli Lilly has continued to focus on innovation and the development of new medicines that address unmet medical needs. His tenure has been marked by the successful launch of several key products, including the diabetes treatment Trulicity and the cancer drug Verzenio. Ricks is also recognized for his commitment to improving global healthcare access, particularly in underserved regions. His strategic initiatives have helped Eli Lilly strengthen its portfolio and maintain a competitive edge in the pharmaceutical industry. As Chair, President, and CEO, Ricks is responsible for steering the overall direction of Eli Lilly, ensuring that the company remains at the forefront of medical innovation while maintaining financial stability. He is a proponent of fostering a culture of diversity and inclusion within the organization, believing that a diverse workforce drives better decision-making and innovation. Ricks' leadership has been instrumental in navigating the challenges of the pharmaceutical landscape, including regulatory hurdles and competitive pressures, while positioning Eli Lilly for long-term success.